(Q43505922)

24 November 2017

title

Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine (English)

1 reference

24 November 2017

1 reference

Greenwald MK

1

1 reference

24 November 2017

Stitzer ML

series ordinal

2

1 reference

24 November 2017

publication date

1 December 1998

1 reference

Drug and Alcohol Dependence

24 November 2017

published in

1 reference

24 November 2017

volume

53

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

17-30

1 reference

Effects of receptor-selective opioids on operant behavior in morphine-treated and untreated rats

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Opioid physical dependence development: effects of single versus repeated morphine pretreatments and of subjects' opioid exposure history

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Kappa receptor mediated opioid dependence in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Butorphanol: a review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hours postmorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Discriminative stimulus effects of narcotics: evidence for multiple receptor-mediated actions

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Supersensitivity to naloxone following acute morphine pretreatment in humans: behavioral, hormonal and physiological effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Comparative pharmacological and biochemical studies between butorphanol and morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Butorphanol precipitates abstinence in morphine dependent rats

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

The physical dependence liability of butorphanol: A comparative study with morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Increased release of excitatory amino acids in rat locus coeruleus in kappa-opioid agonist dependent rats precipitated by nor-binaltorphimine

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

A simple, reliable method for predicting the physical dependence liability of narcotic antagonist analgesics in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Effects of nor-binaltorphimine on butorphanol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Involvement of delta-opioid receptors in physical dependence on butorphanol

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Opioid antagonists and butorphanol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Involvement of kappa-opioid receptors in opioid dependence/withdrawal: studies using butorphanol

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Acute physical dependence: time course and relation to human plasma morphine concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Opioid physical dependence development in humans: effect of time between agonist pretreatments

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Cellular and molecular mechanisms of drug dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ-opioid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Respiratory and circulatory effects of intravenous butorphanol and morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Molecular neurobiology of drug addiction

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Effects of beta-funaltrexamine on butorphanol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Abuse liability studies of opioid agonist-antagonists in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Discrimination of butorphanol and nalbuphine in opioid-dependent humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Psychopharmacology and abuse potential of transnasal butorphanol

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Morphine-like stimulus effects in the monkey: opioids with antagonist properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Substitution and primary dependence studies in animals.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2898%2900104-5

7 January 2021

10.1016/S0376-8716(98)00104-5

Identifiers

DOI

1 reference

24 November 2017

1 reference